Please use this identifier to cite or link to this item:
Title: Hypofractionated stereotactic radiotherapy for benign intracranial tumours of the cavernous sinus.
Epworth Authors: Haghighi, Neda
Dally, Michael
Other Authors: Seely, Anna
Eldho, Paul
Keywords: Radiation Oncology, Epworth HealthCare, Richmond, Victoria, Australia
Cavernous Sinus
Pituitary Neoplasms
Pituitary Cancer
Cancer of the Pituitary
Pituitary Carcinoma
Pituitary Tumors
Pituitary Adenoma
Radiosurgery, Stereotactic
Stereotactic Radiosurgery
Linear Accelerator Radiosurgery
Cranial Nerves
Cranial Neuropathies
Issue Date: Sep-2015
Publisher: Elsevier
Citation: Journal of Clinical Neuroscience 2015 Sep;22(9):1450-5
Abstract: We present our experience with hypofractionated stereotactic radiotherapy (HSRT) using 15 fractions to treat benign conditions of the cavernous sinus (CS) and emphasise the outcome in terms of cranial nerve (CN) function and toxicity for long term safety and efficacy. We performed a retrospective review of prospectively collected data on 112 patients with benign tumours of the CS treated with HSRT between 1 January 1998 and 31 December 2009. While all tumours involved the CS, a separate analysis was undertaken for meningiomas and pituitary adenomas. The median follow-up was 77months (range: 2.3-177). Fifty-seven patients (51%) had a diagnosis of meningioma and 55 (49%) had pituitary adenomas. Prior to HSRT, 82 patients (73%) underwent microsurgery. The median tumour volume was 6.6cm(3) for meningiomas and 3.4cm(3) for pituitary adenomas (interquartile range: 2.8-7.9), and the mean prescribed dose was 38Gy (range: 37.5-40.0) to the tumour margin, delivered in 15 fractions. After HSRT, 57% of all preexisting cranial neuropathies either resolved or improved and 38% remained stable, whereas 5% deteriorated. The diagnosis of meningioma was the only variable associated with recovery of cranial neuropathy (p<0.001). Permanent CN complications occurred in three patients (3%). The 5 and 10year actuarial freedom from progression for patients with meningiomas was 98% and 93%, respectively, and for patients with pituitary adenomas this was 96% and 96%, respectively. We demonstrate low rates of CN morbidity after HSRT and the possibility of resolution or improvement in CN function for common histologies involving the CS.
DOI: 10.1016/j.jocn.2015.03.026
PubMed URL:
ISSN: 0967-5868
Journal Title: Journal of Clinical Neuroscience
Type: Journal Article
Affiliated Organisations: William Buckland Radiotherapy Centre, The Alfred Hospital, Prahran, Victoria, Australia
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
Type of Clinical Study or Trial: Retrospective studies
Appears in Collections:Cancer Services
Radiation Oncology

Files in This Item:
There are no files associated with this item.

Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.